Best Pharmaceuticals for Children Act

Pub. L. 107–109

14 sections of the Code credited to this law, found between Public Law 106-580 and Public Law 107-136.

• 21 U.S.C. § 321 — Definitions; generally
• 21 U.S.C. § 355 — New drugs
• 21 U.S.C. § 355a — Pediatric studies of drugs
• 21 U.S.C. § 355b — Adverse-event reporting
• 21 U.S.C. § 379h — Authority to assess and use drug fees
• 21 U.S.C. § 393a — Office of Pediatric Therapeutics
• 42 U.S.C. § 282 — Director of National Institutes of Health
• 42 U.S.C. § 284k — Clinical research
• 42 U.S.C. § 284l — Enhancement awards
• 42 U.S.C. § 284m — Program for pediatric studies of drugs
• 42 U.S.C. § 285a-2 — 285a–2. Special authorities of Director
• 42 U.S.C. § 290b — Establishment and duties of Foundation
• 42 U.S.C. § 284m–1 — Pediatric Advisory Committee
• 42 U.S.C. § 285a–2 — Special authorities of Director